AntiThrombotic Therapy to Ameliorate Clinical Complications in Community Acquired Pneumonia
Status:
Not yet recruiting
Trial end date:
2029-03-31
Target enrollment:
Participant gender:
Summary
This is an international, open-label, stratified randomized controlled trial with Bayesian
adaptive stopping rules to compare the effects of therapeutic-dose heparin vs. usual care
pharmacological thromboprophylaxis on outcomes in patients admitted to hospital with
community acquired pneumonia (CAP).
Phase:
Phase 3
Details
Lead Sponsor:
University of Manitoba
Collaborators:
Canadian Critical Care Trials Group Canadian Institutes of Health Research (CIHR) Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network Ozmosis Research Inc. Research Manitoba